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Behavioral/Systems/Cognitive
Intra-Amygdala and Systemic Antagonism of NMDA
Receptors Prevents the Reconsolidation of Drug-Associated
Memory and Impairs Subsequently Both Novel and
Previously Acquired Drug-Seeking Behaviors
Amy L. Milton, Jonathan L. C. Lee, Victoria J. Butler, Richard Gardner, and Barry J. Everitt
Behavioural and Clinical Neuroscience Institute, Department of Experimental Psychology, University of Cambridge, Downing Site, Cambridge CB2 3EB,
United Kingdom
The amygdala has long been considered a primary locus in mediating the effects of previously drug-associated stimuli on subsequent
drug-seeking behavior, and the NMDA subtype of glutamate receptor within the amygdala is important for the consolidation of associ-
ations between environmental conditioned stimuli and the effects of addictive drugs. Here we demonstrate that amygdala NMDA
receptors are also necessary for the reconsolidation of drug-associatedmemories. Using a behavioral task that specifically measures the
conditioned reinforcing properties of a previously drug-paired stimulus, we show that infusion of the NMDA receptor antagonist D(-)-
2-amino-5-phosphonopentanoic acid (D-APV) into the basolateral amygdala before a memory reactivation session disrupted the drug-
associated memory and abolished subsequent instrumental responding for conditioned reinforcement. This effect was memory reacti-
vation dependent, and the memory deficit persisted for at least 4 weeks. In contrast, infusion of D-APV immediately after the memory
reactivation session had no effect on subsequent responding for conditioned reinforcement, indicating that NMDA receptors have a
temporally limited role in the reconsolidation process. Furthermore, in molecular studies, we show that the reconsolidation-impairing
effect of D-APV is correlated with downstream reductions in expression of the plasticity-related immediate early gene, zif268.We also
demonstrate that systemic antagonism of NMDA receptors with MK-801 [()-5-methyl-10,11-dihydro-SH-dibenzo[a,d]cyclohepten-
5,10-imine maleate] before memory reactivation subsequently reduced previously acquired instrumental drug-seeking behavior that
depends on drug-associated cues acting as conditioned reinforcers. These data suggest that drugs modulating glutamatergic transmis-
sion at the NMDA receptor may be useful in the future treatment of relapse prevention in drug addiction throughmemory reconsolida-
tion blockade.
Key words:memory reconsolidation; cocaine; self-administration; glutamate; NMDA receptor; zif268
Introduction
The impact on addictive behavior of associations between envi-
ronmental conditioned stimuli (CSs) and self-administered
drug, arising from repeated pairings, is central to several theories
of addiction (Stewart et al., 1984; O’Brien et al., 1992; Robinson
and Berridge, 1993; Everitt et al., 2001). Because memories elic-
ited by exposure to drug CSs are a major contributor to relapse
(Stewart et al., 1984; O’Brien et al., 1992; Everitt et al., 1999),
treatments that disrupt drug-associated memories could act as a
pro-abstinence or anti-relapse therapy (Lee et al., 2005, 2006a).
Memory reconsolidation, the process by which memories be-
come destabilized by reactivation at retrieval and require restabi-
lization to persist (Lewis, 1979; Nader, 2003), provides a key
mechanismonwhich such treatmentsmight act (Lee et al., 2005),
and the NMDA subtype of glutamate receptor (NMDAR) is a
promising target for drugs designed to disrupt memory
reconsolidation.
The NMDAR has been recently implicated in memory recon-
solidation. Antagonism of NMDARs has been shown to be am-
nestic when given in conjunctionwithmemory retrieval, suggest-
ing their involvement in the reconsolidation of spatial memories
(Przybyslawski and Sara, 1997), sucrose-associated memories
(Lee and Everitt, 2008), fear-associated memories (Ben Mamou
et al., 2006; Lee et al., 2006b), and drug-conditioned place pref-
erencememories (Kelley et al., 2007; Sadler et al., 2007). Further-
more, antagonism at the NMDAR has been shown to reduce the
expression of the plasticity-related immediate early gene zif268
during classical conditioning (Mokin and Keifer, 2005), which is
also increased on the retrieval of drug-associated memories
(Thomas et al., 2003). The knockdown of zif268within the baso-
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lateral amygdala (BLA) also impairs drug-associated memory re-
consolidation (Lee et al., 2005). Therefore, in addition to inves-
tigating the behavioral effects ofNMDARantagonism atmemory
retrieval on drug-associated memories, we also investigated the
effects of NMDAR antagonism on the downstream expression of
zif268.
The neural site at which systemic NMDAR antagonism dis-
rupts drug-associated memory reconsolidation has not yet been
defined, but the BLA is likely to be a primary locus. The BLA
mediates conditioned reinforcement, because it has been shown
to be critical for themechanism bywhich drug-associated stimuli
affect instrumental behavior (Cador et al., 1989; Burns et al.,
1993), including cue-induced reinstatement of cocaine-seeking
behavior in models of relapse (Meil and See, 1997; Kantak et al.,
2002). Therefore, in the study reported here, we have used both
intra-BLA and systemic NMDAR antagonism in two models of
responding for drug-associated conditioned reinforcers (Di
Ciano and Everitt, 2004; Lee et al., 2005, 2006a; Lu et al., 2005) to
investigate the reconsolidation of CS–cocaine memories, and es-
pecially whether the BLA is a primary locus of the amnestic effect
of systemically administered NMDAR antagonists. We also mea-
sured the expression of zif268 to investigate the cellular correlates
of the behavioral effects of intra-BLA NMDAR antagonism.
Materials andMethods
Subjects
Subjects were male Lister Hooded rats (Charles River) weighing at least
250 g at the time of surgery. Each animal was housed singly after surgery
in a vivarium on a reverse light/dark cycle (lights on at 7:00 P.M.). Sub-
jects were food restricted, being fed after training or testing, and allowed
access to water ad libitum except during training and testing sessions. All
experiments were conducted in accordance with the United Kingdom
Animals (Scientific Procedures) Act of 1986 (PPL 80/1767).
Surgery
Rats were implanted with a chronic, indwelling intravenous catheter
targeting the right jugular vein and, for experiment 1, bilateral cannulas
located just dorsal to the basolateral amygdala. The coordinates for can-
nula implantation were anteroposterior 2.6 mm and mediolateral
4.5 mm (relative to bregma), and dorsoventral 5.6 mm (relative to
dura). Details of the surgical procedures can be found in the article by Lee
et al. (2005). A recovery period of 7 d was imposed before behavioral
training and testing began.
Infusions
Infusions were performed using a syringe pump and 5 l Hamilton
syringes, connected to injectors (28 gauge, projecting 2 mm beyond the
guide cannulas) by polyethylene tubing. Infusions of the competitive
NMDAR antagonist D(-)-2-amino-5-phosphonopentanoic acid (D-
APV) (5 g/0.5 l/side, 0.25 l/min; Sigma-Aldrich) or sterile PBS ve-
hicle (0.5 l/side, 0.25 l/min) were begun 30 s after the insertion of the
injectors and performed over 2 min. One minute of waiting time was
imposed from the end of the infusion to the removal of injectors to allow
diffusion of the solution away from the infusion site. This dose, admin-
istered directly to the BLA, has been shown to disrupt the acquisition of
conditioned fear memory (Matus-Amat et al., 2007). Rats were habitu-
ated to the infusion procedure using the vehicle solution (0.5 l/side,
0.25 l/min) twice during self-administration training, always before
conditioning.
Injections
Because D-APV poorly penetrates the CNS when administered systemi-
cally, an alternative NMDAR antagonist, ()-5-methyl-10,11-dihydro-
SH-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801), was used
for systemic administration. Rats in the reactivated groups were given
intraperitoneal injections of MK-801 (0.1 mg/kg; Sigma-Aldrich) or an
equivalent volume of 0.9% saline vehicle 30 min before the memory
reactivation session. Non-reactivated groups were injected on the same
day and were immediately returned to their home cages without experi-
encing the memory reactivation session. This dose of MK-801 has been
demonstrated previously to lead to deficits in the reconsolidation of
aversive and appetitive memories (Lee et al., 2006b; Lee and Everitt,
2008).
Behavioral procedures
Experiment 1a: acquisition of a new instrumental response for a previously
drug-paired conditioned reinforcer.Ratswere trained in operant chambers
(Med Associates) as described previously (Hellemans et al., 2006). Self-
administration training took place over nine daily sessions, controlled by
the Whisker control system. Each head entry (nosepoke) into the food
magazine was recorded and reinforced on a fixed-ratio 1 (FR1) schedule
with a presentation of a 20 s light CS and a 5.83 s infusion of cocaine (0.25
mg/0.1ml), duringwhich time the houselight was not illuminated.Nose-
pokes made during the 20 s of CS presentation were not reinforced. The
end of this time-out periodwas signaled by the illumination of the house-
light. The rats were permitted a maximum of 30 cocaine infusions, after
which the houselight was turned off and the session ended. If the rats did
not reach this limit, the session terminated 60 min after it started.
Memory reactivation took place on the day after the final session of
self-administration training. For the infusions of D-APV given before
memory reactivation, the reactivation session began immediately after
the end of the infusion procedure. Rats receiving postreactivation (PR)
infusions were infused immediately after the end of the reactivation ses-
sion. In the reactivation session, all of the parameters were the same as
during training, except that the session length was 15 min, and the sy-
ringe pump delivered saline instead of cocaine. Non-reactivated controls
were given intracerebral infusions and returned to the home cage.
Testing for conditioned reinforcement by measuring the acquisition
of a new instrumental response reinforced by the CS (ANR) began the
day after thememory reactivation session. Ratswere returned to the same
operant chamber that had previously been used for training and reacti-
vation, but this now contained two novel levers. Depression of the inac-
tive lever, which was located on the same side as the CS light to avoid the
confound of pavlovian approach behavior (Parkinson et al., 2005), pro-
duced no programmed consequence but was recorded for comparison to
active lever presses. Active lever presses produced a 1 s illumination of the
previously drug-paired light CS on a variable ratio 1–3 schedule, during
which time the houselight was switched off. The abbreviated CSwas used
because this is optimal for the CS to act as a conditioned reinforcer
(Mackintosh, 1974). There was no limit to the number of CS presenta-
tions during ANR; the rats remained in the chamber for 30 min. ANR
testing was conducted on PR days 1, 2, 5, and 8 and, if an impairment was
evident, on PR days 15, 22, and 29.
Experiment 1b: analysis of Zif268 expression after antagonism at the
NMDAR. Six groups of rats underwent the same surgery and behavioral
training procedures as described for experiment 1a, but they were killed
2 h after the intracerebral infusions for assessment of Zif268 protein
levels in the basolateral amygdala. All infusion parameters and, where
applicable, the parameters of the reactivation session, were the same as in
experiment 1a. After killing by exposure to a rising CO2 concentration,
and decapitation, the brains were rapidly extracted and immediately fro-
zen on dry ice.
Experiment 1c: conditioned place aversion.To ensure that any reduction
in responding for the previously drug-paired CS was attributable to a
deficit in CS–drug memory reconsolidation and not countercondition-
ing of any putative aversive effects of NMDAR antagonism to the previ-
ously drug-paired CS, the ability of the D-APV infusion to act as an
unconditioned stimulus in the conditioning of a place aversion was
investigated.
Before each session, the two-compartment conditioned place aversion
apparatus was cleaned with TriGene spray to remove any olfactory cues
from previous sessions. The rats always began the sessions in the central
compartment of the chamber, before being released into the appropriate
chamber(s). On the day before conditioning, the rats were habituated to
the apparatus for 20 min, with the time spent in each compartment
measured by the experimenter on a video link in an adjacent room. On
the conditioning day, the rats were confined in one of the compartments
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for 20 min immediately after an intra-BLA in-
fusion of D-APV (0.5 g/0.5 l, 0.25 l/min).
The conditioned side was arbitrarily assigned to
each rat, with the groups being matched so that
times spent in the to-be-conditioned compart-
ment during the habituation session were
equal. On the following day, the rats’ prefer-
ences for each compartment were tested by re-
exposing them to the apparatus for 20min, and
recording the time spent in each compartment.
Experiment 2: maintenance of cocaine-seeking
with conditioned reinforcement. Rats were
trained in operant conditioning chambers
(Med Associates) as described previously (Lee
et al., 2006a). Rats underwent 10 d of cocaine
self-administration training in which depres-
sion of the “active” lever (counterbalanced left
or right) led to a cocaine infusion (0.25 mg/0.1
ml delivered over 5.83 s) and a 20 s illumination
of the CS–light, which was located above the
active lever on a FR1 schedule of reinforcement.
Responding on a second lever, the “inactive”
lever, although recorded, had no programmed
consequences. The rats were limited to 30 CS–cocaine pairings in a ses-
sion. If this limit was not reached, the session terminated 60 min after it
started.
Memory reactivation took place 2 d after the completion of cocaine
self-administration training. The rats were returned to the operant con-
ditioning chambers used during training for a 30 min reactivation ses-
sion. The parameters of this session were the same as for training, except
that depression of the active lever led to a 0.1ml infusion of saline, rather
than cocaine, paired with the 20 s CS–light. Non-reactivated control
groups received injections and were immediately returned to the home
cage.
Testing for cocaine seeking with conditioned reinforcement occurred
6 d after the completion of self-administration training. The rats were
returned to the operant conditioning chambers used for training with
both levers presented. Depression of the active lever led to the presenta-
tion of an abbreviated 1 s light CS and lever retraction. Pressing of the
inactive lever had noprogrammed consequence, butwas recorded to give
an indication of generalized activity. There was no limit to the number of
CS presentations during the test, the session being terminated 60 min
after it had started. The data from the test session were analyzed in four,
15 min time bins.
Histological assessment of cannula placements (experiments 1a
and 1c)
After the end of testing, rats with intracerebral cannulas that were not
used for experiment 1b were killed with an overdose of sodium pento-
barbital [1.5 ml of Dolethal (Rhone Merieux) per animal] and perfused
with 0.01 M PBS followed by 4% paraformaldehyde. Coronal sections at
60 m were stained with cresyl violet so that the placements could be
verified by light microscopy. Subjects were only included if there was
evidence of the injector tip being placed within the basolateral amygdala,
and there was no bilateral damage to the BLA or other areas of the brain.
The cannula placements in the animals in experiment 1b were verified by
eye before amygdala dissection.
Western blotting (experiment 1b)
After being killed, the rats were decapitated, and the brains were ex-
tracted and frozen on dry ice before being stored at 80°C. After mild
thawing, the cannula placements were verified by eye, and 1mm sections
were taken using an adjustable brain matrix (Braintree Scientific). The
amygdala was dissected bilaterally using a 1 mm brain punch set (Stoelt-
ing), and the tissue lysates and Western blotting were performed as de-
scribed previously (Lee et al., 2004). The proteinswere separated on 7.5%
Tris-HCl gels using a constant voltage of 80 V and then transferred to
nitrocellulose membranes at a constant current of 100 mA for 1 h. The
blots were blocked in a 0.01 M Tris-buffered saline solution containing
0.05% Tween 20 (TBST) that also contained 5% nonfat milk. The TBST
solution was used for all subsequent incubations and washes. The blots
were first incubated in primary antibodies [Zif268, 1:10,000 (a kind gift
from G. I. Evan, University of California, San Francisco, San Francisco,
CA); -actin, 1:20,000] and then secondary antibodies [goat anti-
rabbit and goat anti-mouse IgG (whole-molecule)–peroxidase conju-
gates, 1:10,000]. The blots were developed by enhanced chemilumines-
cence and opposing to autoradiographic film. Images of these
autoradiographs were captured using a Qicam 12-bit mono digital cam-
era (QImaging) and quantified using MCID Core 7.0 software (InterFo-
cus Imaging). Autoradiographs were developed so as to be linear in the
range used to analyze the density of -actin and Zif268. For each sample,
the amount of protein was analyzed bymeasuring the optical density and
the area of the protein band, and these were multiplied to derive a value
for the amount of protein for both -actin and Zif268. Although the
amount of protein in each sample was normalized before Western blot-
ting using a NanoDrop ND-1000 spectrophotometer (LabTech Interna-
tional), any variation in loading was corrected by deriving a normaliza-
tion factor (average amount of -actin/sample amount of -actin) for
each sample. This factor was then used to correct the raw sample amount
of Zif268, which was finally normalized against the average control level
of Zif268 expression in the vehicle group.
Statistical analysis
All data were analyzed using SPSS 11.5 for Windows (SPSS). Unless
otherwise stated, the data were analyzed using a three-way repeatedmea-
sures ANOVA, with Lever and Session as within-subject factors, and
Treatment (D-APV vs PBS vehicle) or Group (vehicle, CS present vs
MK-801, CS present vs vehicle, CS omitted) and Reactivation (reacti-
vated vs non-reactivated) as the between-subject factors. Any deviations
from sphericity were corrected using the Greenhouse-Geisser correction
if  0.75, and theHuynh-Feldt correction if  0.75, as recommended
by Cardinal and Aitken (2006). Where appropriate, Sidak-corrected
pairwise comparisons were performed; the Sidak correction is the math-
ematically correct version of the Bonferroni correction (Cardinal and
Aitken, 2006). Student’s t tests (two-tailed) were used to compare means
of the experimental groups in the memory reactivation session, and the
molecular data were analyzed using one-tailed t tests, because we specif-
ically predicted a reduction in Zif268 expression levels in the group re-
ceiving D-APV treatment before memory reactivation.
Results
Experiment 1a: acquisition of a new response for a previously
drug-paired conditioned reinforcer
All of the cannula placements were within or adjacent to the
boundaries of the BLA. Only rats with patent cannulas that were
Figure 1. Location of the injector tips in the BLA. Gray circles represent vehicle-infused animals; black circles represent D-APV-
infused animals.
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placed either within or adjacent to the boundaries of the basolat-
eral amygdala were included in the analysis (Fig. 1).
Intra-amygdala NMDAR antagonism at memory reactivation
persistently disrupted the ability of the previously drug-paired CS
to act as a conditioned reinforcer, in a reactivation-dependent
manner
Treatment with the NMDA receptor antagonist D-APV immedi-
ately before the memory reactivation session led to a subsequent
persistent impairment in the conditioned reinforcing properties
of the previously drug-paired CS (Fig. 2a). The rats administered
D-APVbeforememory reactivation did not discriminate between
the lever that produced the previously drug-paired CS (active
lever) and the lever that had no programmed consequences (in-
active lever), in contrast to the vehicle-infused, reactivated con-
trol group (Sidak-corrected pairwise comparisons, vehicle: p 
0.01; D-APV: p  0.356). The deficit induced by D-APV was re-
activation dependent (treatment reactivation lever: F(1,24)
4.849, p  0.05), because although there was a main effect of
treatment with the NMDAR antagonist in the reactivated groups
(treatment: F(1,10) 6.488, p 0.05; lever treatment: F(1,10)
5.269, p  0.05), there was no such difference in the non-
reactivated condition (treatment: F  1; lever: F(1,14)  20.878,
p 0.001; lever treatment: F(1,14) 1.405, p 0.256) (Fig. 2b).
Sidak-corrected pairwise comparisons supported the deficit in
lever pressing seen in the reactivated, D-APV-treated group as
being specifically related to the presentation of the previously
drug-associated cue, because the reactivated vehicle-treated
group pressed the active lever more than did the reactivated
D-APV-treated group ( p  0.028), whereas both treatment
groups showed the same levels of inactive lever pressing ( p 
0.142).
Postmemory reactivation NMDAR antagonism had no effect on
the acquisition of responding with conditioned reinforcement
Infusions of D-APV immediately after the memory reactivation
session did not impair subsequent instrumental responding for
conditioned reinforcement (Fig. 2c). Because there were no sig-
nificant differences between the groups by day 8 after reactiva-
tion, subsequent testing was not conducted. All of the rats, both
vehicle- and D-APV-treated, showed a preference for the active
lever over the inactive lever (lever: F(1,6) 8.148, p 0.05; treat-
ment: F(1,6)  2.934, n.s.; lever  session: F(3,18)  3.246, p 
0.05; lever treatment: F 1).
Subsequent performance of the previously learned instrumental
response for drug was not reduced by NMDAR antagonism before
memory reactivation
Because a deficit in responding for subsequent conditioned rein-
forcement was found in the experimental group given D-APV in
conjunction with memory reactivation, the primary instrumen-
tal response that had previously been reinforced with drug, nose-
poking, was also analyzed for the experimental groups that re-
ceived infusions before the memory reactivation session.
However, in contrast to the deficit observed with the acquisition
of a new instrumental response with conditioned reinforcement,
D-APV given in conjunction with memory reactivation did not
reduce the number of nosepokes, the previously acquired instru-
mental behavior, relative to the vehicle-infused control group,
during the subsequent test phase (Fig. 3) (treatment: F(1,10) 
2.624, n.s.; session  treatment: F(2.34,23.4)  2.089, n.s.). How-
ever, nosepoking did extinguish throughout the course of testing
(session, F(2.34,23.4) 5.324, p 0.01).
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Figure 3. Performance of the previously drug-reinforced instrumental behavior, nosepok-
ing, during subsequent testing for conditioned reinforcement was not affected by the admin-
istration of D-APV before memory reactivation (vehicle, n 5; D-APV, n 7). Data are pre-
sented as mean SEM.
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Figure 2. Assessment of the conditioned reinforcing properties of a previously cocaine-paired CS using the acquisition of a new instrumental response for conditioned reinforcement. a, The
number of lever presses made for the conditioned reinforcer (active lever) and for no reinforcement (inactive lever)29 d after treatment by rats infused with D-APV or PBS vehicle before the
memory reactivation session (vehicle, n 5; D-APV, n 7). b, The number of lever pressesmade for conditioned reinforcement by rats infused but not reactivated (vehicle, n 9; D-APV, n 7).
c, The number of lever presses made for conditioned reinforcement by rats infused immediately after the memory reactivation session (n 4 per group). Data are presented as mean SEM.
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There were no differences in cocaine self-administration between
the experimental groups
There were no differences in training performance between any
of the experimental groups and their vehicle controls (data not
shown). There were no differences between the experimental
groups that received pre-reactivation infusions and those that
were non-reactivated in terms of either CS–cocaine pairings ex-
perienced during training (treatment: F 1; reactivation: F 1;
treatment reactivation: F 1) or the number of instrumental
responses (nosepokes) made for cocaine during self-
administration training (treatment: F  1; reactivation: F  1;
treatment reactivation: F(1,24) 1.317, n.s.).
Training performance was equivalent between the vehicle and
D-APV experimental groups to be given the infusion immediately
after memory reactivation, with no differences in CS–cocaine
pairings experienced during self-administration (treatment: F
1; session  treatment: F  1) or nosepokes made for cocaine
(treatment: F(1,6) 1.692, n.s.; session treatment: F 1).
Because the amount of CS exposure has been suggested to
influence the degree ofmemory reactivation (Suzuki et al., 2004),
it was important to verify that there were no differences in the
number of CS presentations experienced during the memory re-
activation session. Thus, the mean number of nosepoke-CS pre-
sentations experienced by each experimental group was com-
pared with the appropriate control group using independent
samples t tests. There were no differences in CS presentations for
the reactivated groups given infusions before memory reactiva-
tion (data not shown; vehicle, 17.2 1.66, D-APV, 14.0 2.73,
t(10)  0.90, n.s.) or for the groups infused after the memory
reactivation session (data not shown; vehicle, 12.5  2.75,
D-APV, 12.5 3.07, t(6) 0.43, n.s.).
Experiment 1b: Zif268 expression levels after
NMDAR antagonism
Intra-amygdala D-APV infused before memory reactivation re-
duced Zif268 expression, whereas D-APV administered without
memory reactivation did not
Based on the findings from experiment 1a and our previous data
showing a reduction in conditioned reinforcement with knock-
down of the immediate early gene zif268 (Lee et al., 2005), we
predicted that NMDAR antagonism was disrupting memory re-
consolidation through downregulation of downstream zif268 ex-
pression. The molecular data supported these predictions, be-
cause D-APV infused immediately before memory reactivation
reduced the levels of Zif268 expression measured 2 h after the
infusion (treatment: t(6) 2.094, p 0.05), whereas D-APV ad-
ministered without a memory reactivation session had no effect
(treatment: t(6)  0.044, n.s.) (Fig. 4a,b). In contrast, post-
reactivation infusion of D-APV had no effect on the subsequent
levels of Zif268 expression (treatment: t(2.1)  1.012, n.s.) (Fig.
4c), which is consistent with the behavioral finding that rats in-
fused with D-APV after memory reactivation showed no subse-
quent reduction in the conditioned reinforcing properties of the
previously drug-paired CS (Fig. 2c).
There were no differences in cocaine self-administration between
the experimental groups
There were no differences in the training experience between any
of the test and control groups. All of the experimental groups
learnt the association between cocaine and the CS during train-
ing, because there were no differences in their training perfor-
mance, either in terms of the number of CS–cocaine pairings
experienced during training (data not shown; treatment: F  1
for pre-reactivation infused groups, non-reactivated groups, and
post-reactivation infused groups) or in the number of nosepokes
made for cocaine (data not shown; treatment: F  1 for pre-
reactivation infused group and postreactivation infused
group, F(1,6) 2.249, n.s. for the non-reactivated group).
There were also no differences in the number of CS presenta-
tions experienced during the memory reactivation session for
those groups that experienced it [data not shown; infusions be-
fore memory reactivation: vehicle, 17.0  2.74, D-APV, 20.0 
1.15, t(6)  0.801, n.s.; infusions after memory reactivation: ve-
hicle, 18.0 0.91, D-APV, 21.3 1.20, t(5) 2.259, n.s.].
Experiment 1c: intra-BLA NMDAR antagonism does not
induce an aversive state
Neither infusion of PBSnor infusion of D-APVproduced aversive
effects sufficient to condition a place aversion (Fig. 5). The time
spent on the paired side was the same at test after the condition-
ing session as it was in the habituation session, before condition-
ing, and there were no differences between the rats infused with
PBS and those infused with D-APV (treatment: F 1; session
treatment: F 1; session: F 1).
Experiment 2: performance of a previously acquired cocaine-
seeking instrumental response with conditioned
reinforcement
Overall analysis of the 1 h test session revealed that there was a
pronounced within-session extinction of the effect of the previ-
ously drug-paired CS on responding that may have resulted in a
floor effect in the vehicle group, reducing statistical power
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Figure 4. Analysis of Zif268 expression levels using Western blots. Representative Western blots are shown above bar charts, quantifying levels of Zif268 and -actin expression relative to
controls. White squares represent vehicle-infused animals; black squares represent D-APV-infused animals. a, Administration of the NMDAR antagonist D-APV immediately before memory
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(bin: F(2.69,69.8) 30.013, p 0.001; drug: F 1; drug reacti-
vation: F  2.935, p  0.099). Therefore, the first 15 -min time
bin was analyzed separately.MK-801, given beforememory reac-
tivation, reduced cue-maintained cocaine-seeking 3 d later (Fig.
6a) butMK-801 injection without amemory reactivation session
was insufficient to impair lever pressing (Fig. 6b) (treatment 
reactivation: F(1,26) 5.044, p 0.05). Consistent with this, there
was no main effect of Treatment in the non-reactivated groups
(treatment: F(1,10) 1.045, n.s.). However, whereas MK-801 ad-
ministered at memory reactivation impaired responding relative
to saline-treated rats (vehicle vs MK-801 reactivated groups,
treatment: F(1,16)  5.319, p  0.05), there was no difference in
lever pressing compared with a reactivated, vehicle-treated con-
trol group in which the CS was omitted at test (MK-801 vs CS–
omission group, group: F(1,16) 3.287, n.s.; lever group: F(1,16)
 4.236, n.s.). Solely comparing responding on the active levers,
the rats that received MK-801 at reactivation were intermediate
in their responding, being not significantly different from either
the group that received vehicle at reactivation ( p 0.061) or the
group that received vehicle at reactivation, but had the CS omit-
ted at test ( p 0.063). All of the rats discriminated between the
active and inactive levers (all p values  0.01), indicating that
performance of the instrumental response that had previously
been reinforced with self-administered cocaine was not affected
by the administration of MK-801 before memory reactivation.
Rats in the CS–omission group also showed discrimination be-
tween the two levers (lever: F(1,8)  97.441, p  0.001), further
suggesting that in groups presented with the CS during test, the
CS reinforced and enhanced the vigor of active lever pressing,
although responding still occurred at lower rates in its absence.
Before testing and memory reactivation, all rats learned the
instrumental response for intravenous cocaine during training
(data not shown; lever: F(1,39) 166.12, p 0.001; group: F 1;
reactivation: F  1; group  reactivation: F 1). Similarly, all
groups had equivalent exposure to the CS during training (data
not shown, average CS presentations between 162.8 and 192.6;
group: F 1; reactivation: F 1; group reactivation: F 1).
As for experiment 1, there were no differences between the
groups in behavior during the reactivation session. Although
MK-801 can produce the locomotor side effect of hyperactivity
(Whishaw and Auer, 1989) this did not influence lever pressing
during the memory reactivation session (data not shown; Lever:
F(1,24)  76.77, p  0.001; group: F  1). There were also no
differences in CS exposure during the memory reactivation ses-
sion (data not shown; group, F(2,24) 1.980, n.s.).
Discussion
The data reported here demonstrate that activity at the NMDA
subtype of glutamate receptor (NMDAR) in the BLA is necessary
for drug-associated memory reconsolidation. Antagonism of
NMDARs in conjunction with a memory reactivation session
strongly attenuated the conditioned reinforcing properties of the
previously drug-pairedCS and so prevented it subsequently from
supporting both new instrumental behavior, which can be con-
sidered a measure of flexible drug seeking (Di Ciano and Everitt,
2004) and the performance of a previously acquired instrumental
drug-seeking response, whichmodels an aspect of relapse behav-
ior. The NMDAR dependence of the reconsolidation process was
shown to be time-limited; NMDAR antagonism immediately af-
ter the memory reactivation session had no effect on memory
reconsolidation as assessed by the ability of the CS to support the
subsequent acquisition of a new instrumental response. Further-
more, we have demonstrated this amnestic effect after intra-BLA
infusions of an NMDAR antagonist, providing clear evidence
that the BLA is a primary locus of action for the effects of system-
ically administered NMDAR antagonists on CS–drug memory
reconsolidation.
The specific targeting of the BLA in experiment 1 of this study
also allows for direct comparison with studies of the genetic
mechanisms of memory reconsolidation, because knockdown of
the immediate early gene zif268 within the BLA also profoundly
disrupts drug-associated memory reconsolidation (Lee et al.,
2005, 2006a). Thus, bothNMDARantagonism and zif268 knock-
down in conjunction with memory reactivation abolished the
conditioned reinforcing properties of previously drug-paired
CSs, subsequently impairing the acquisition of new drug-seeking
behavior and attenuating previously learned instrumental re-
sponding for drug. Western blot analysis of Zif268 expression
levels (experiment 1c) revealed that there was a downregulation
of Zif268 expression when the NMDAR antagonist D-APV was
administered intracerebrally immediately before memory re-
trieval, but not when D-APV was administered after memory
retrieval, or in the absence of memory retrieval. These data
strongly suggest that the effect of activity at NMDARs in the
reconsolidation of drug-associated memories is mediated down-
stream by the plasticity-related immediate early gene zif268.
Our findings demonstrate that antagonism of NMDARs be-
fore memory retrieval specifically disrupted CS–drug memory
reconsolidation, because administration of the NMDAR antago-
nist without the reactivation of the CS–drug memory had no
effect on the capacity of the previously drug-paired CS to func-
tion as a conditioned reinforcer and support the acquisition of a
new instrumental response. Indeed, responding for the previ-
ously drug-paired CS by animals infused, but not reactivated,
increased over time, described previously as the “incubation of
cocaine craving” by Grimm et al. (2001). A possible alternative
account of the persistent impairment in instrumental responding
shown by the experimental group receiving infusions of D-APV
beforememory reactivation, that the D-APV infusion induced an
aversive state that acted to countercondition the CS, can be dis-
counted, because no place aversion could be conditioned as a
result of the intra-amygdala D-APV infusion.
In addition to our use of a behavioral procedure that isolates
conditioned reinforcement and so models the acquisition of new
drug-seeking responses that may greatly affect the propensity to
relapse (Di Ciano and Everitt, 2004), in experiment 2 we used a
more frequently studied and translationally relevant model of
relapse to a previously acquired drug-seeking response (Lu et al.,
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Figure 5. Time spent on the infusion-paired side of a two-compartment apparatus 1 d
before the conditioning session (Baseline) and 1 d after the conditioning session (Test). The
dotted line represents equal amounts of time being spent on the paired and unpaired sides
(vehicle, n 4; D-APV, n 5). Data are presented as mean SEM.
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2005, 2006; Fuchs et al., 2006). Moreover,
we studied the effects of a systemically ad-
ministered NMDAR antagonist, MK-801,
because systemic administration of phar-
macological agents is likely to be of greater
translational utility. The results of experi-
ment 2 showed that it was possible to re-
duce the ability of a previously drug-
paired CS to trigger and maintain
instrumental responding previously rein-
forced by drug, through the disruption of
the reconsolidation of CS–drugmemories
with MK-801. MK-801 administered be-
fore the memory reactivation session im-
paired subsequent lever pressing for the
first 15 min of the subsequent test session,
before the floor effect produced by within-
session extinction. This effect of MK-801
was reactivation-dependent and, more-
over, the responding of the MK-801-
treated group did not differ from that of a
control group inwhich theCSwas omitted
during test. Thus the reduction of drug seeking after MK-801
treatment was equivalent to omission of the CS altogether, sug-
gesting that the treatment disrupted selectively the ability of the
CS to influence drug-seeking responses. This effect was most
clearly seen during the first 15 min of the test session, when
cue-maintained drug seeking was highest in the vehicle group; it
is possible that a larger dose of MK-801, or another NMDAR
antagonist, may reduce this cue-maintained responding over a
longer period of time. However, both theMK-801 andCS–omis-
sion groups continued to respond on the active lever, which is
consistent with findings suggesting that instrumental memories
apparently do not undergo a reconsolidation process (Hernan-
dez and Kelley, 2004), and with our previous findings with
knockdown of the plasticity-related immediate early gene zif268
in the amygdala (Lee et al., 2006a). Furthermore, in experiment 1,
there was no effect of NMDAR antagonism immediately before
retrieval on subsequent nosepoking behavior, which had been
reinforced previouslywith cocaine. This suggests that instrumen-
tal responding was not disrupted by the manipulations reported
here, but rather that the effects of the drug-associated stimuli on
behavior were attenuated, thus leading to a reduction in instru-
mental responding.
The impairment in CS–drug memory reconsolidation reported
here is consistent with the finding that MK-801 can disrupt the re-
consolidation of a cocaine-conditioned place preference (Kelley et
al., 2007). However, the results of the present study provide an ad-
vance in at least two respects. First, because conditioned place pref-
erence (CPP) may be supported by a number of different associa-
tions and behavioral responses, including pavlovian conditioned
approach, reward expectancy, and even conditioned reinforcement
(Everitt andRobbins, 1992; Schechter andCalcagnetti, 1993), aswell
as both contextual and discrete cue influences (Ito et al., 2006), it is
not clear what impairments in CPP reflect in psychological terms,
norhowan impairment inCPPrelates to the instrumentalbehaviors
of drug seeking and drug taking. In contrast, experiment 1 specifi-
cally demonstrated that the CS–drug association was disrupted, be-
cause this is the only association that supports the acquisition of a
new response for conditioned reinforcement (Mackintosh, 1974).
Furthermore, the results demonstrated that even well established
drugmemories can be disrupted. In contrast to the CPP procedure,
inwhich rats are typically administered three to four injections of an
addictive drug (Kelley et al., 2007), we have shown here that CS–
drug memory reconsolidation can be disrupted after the self-
administration of cocaine, and after extensive (180–300) CS–co-
caine pairings. These data strongly suggest that the disruption of
CS–drug memory reconsolidation with NMDAR antagonists in a
realistic animal model of drug-seeking behavior is a feasible thera-
peutic strategy in human addicts trying to achieve abstinence.
Our data support the hypothesis that NMDARs within the
BLA are necessary for the restabilization of drug-associated
memories, because antagonism of these receptors prevented the
memory from reconsolidating. The results are consistent, there-
fore, with our previous demonstration that systemic NMDAR
antagonismwithMK-801 disrupts CS–fearmemory reconsolida-
tion (Lee et al., 2006b) and cue-maintained sucrose seeking (Lee
and Everitt, 2008). However, the present results and our previous
work (Lee et al., 2006b) are in contrast to the finding that infu-
sions of either D-APV or the NR2B-specific NMDAR antagonist
ifenprodil before memory reactivation apparently prevent the
destabilization of aCS–fearmemory, protecting the “reactivated”
memory from the amnestic effects of anisomycin (BenMamou et
al., 2006). It is not yet clear whether these discrepant results re-
flect differences in the selective involvement ofNMDAR subtypes
in memory reconsolidation, procedural differences between the
studies, or different cellular andmolecular mechanisms underly-
ing CS–drug and CS–fear memory reconsolidation.
Our data also differ from previous studies investigating the ne-
cessity of the NMDAR inmemory reconsolidation with our finding
that NMDAR antagonism was only sufficient to disrupt drug-
associated memory reconsolidation if it was administered before,
and not immediately after, the memory reactivation session. This
contrasts with studies of the reconsolidation of object recognition
memory (Akirav and Maroun, 2006) and odor–reward memory
(Torras-Garcia et al., 2005), in which the central administration of
the NMDAR antagonist APV immediately after thememory reacti-
vation session was sufficient to produce subsequent memory im-
pairments. These apparent temporal differences inNMDARdepen-
dence may be related to the length of the reactivation sessions. The
studies inwhichpostreactivationNMDARantagonismwas foundto
disrupt memory reconsolidation used brief memory reactivation
sessions [5minand90s, respectively, forAkiravandMaroun, (2006)
and Torras-Garcia et al. (2005)] compared with experiment 1, in
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Figure 6. Cue-induced relapse to cocaine seeking. a, Lever pressing during test by rats that had received injections of MK-801
or saline vehicle 30 min before the memory reactivation session. Inactive lever presses had no consequence; active lever presses
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which the reactivation session lasted 15 min. This implies that the
hypothesized restabilization process mediated by NMDARs occurs
rapidly after the memory has destabilized, suggesting that in the
present study, thememoryhad already restabilized before the endof
the reactivation session.
In conclusion, we have shown that rats that have previously
learned to self-administer cocaine and have extensive CS–drug-
pairing experience can have their CS-maintained drug-seeking be-
havior reduced by undergoing a single treatment with an NMDAR
antagonist, in conjunction with a drug-memory reactivation ses-
sion, and that the effects ofNMDARantagonismare correlatedwith
reductions in the downstream expression of the immediate early
gene zif268.We have identified thatNMDARswithin the BLA, a site
known to be involved with conditioned reinforcement, drug mem-
ory consolidation, and reconsolidation, are necessary for this effect,
and that systemic administration of an NMDAR antagonist during
memory reactivation is sufficient to produce a reduction in drug-
seeking behavior. Therefore, these results indicate thatNMDARan-
tagonism may be a translationally relevant form of relapse preven-
tion therapy in abstinent drug addicts.
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